18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This follow-up study continues to observe patients who have completed the phase 1 trial of
AADvac1, for another 18 months.
Long-term safety and behavior of the immune response to AADvac1 over time are the main points
of interest.
AADvac1 is a vaccine directed against pathologically modified Alzheimer tau protein that is
the main constituent of neurofibrillary tangles (NFTs), and is intended to be a
disease-modifying treatment for Alzheimer's disease, i.e. to halt its progress.
As this study is a Phase I study focused on tolerability and safety, efficacy will be
assessed in an exploratory manner.